Display options
Cite
Blackledge GR. Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company. Zentralbl Gynakol. 2005;127(6):385-8doi: 10.1055/s-2005-836858.
Blackledge, G. R. (2005). Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company. Zentralblatt fur Gynakologie, 127(6), 385-8. https://doi.org/10.1055/s-2005-836858
Blackledge, G R. "Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company." Zentralblatt fur Gynakologie vol. 127,6 (2005): 385-8. doi: https://doi.org/10.1055/s-2005-836858
Blackledge GR. Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company. Zentralbl Gynakol. 2005 Dec;127(6):385-8. doi: 10.1055/s-2005-836858. PMID: 16341982.
Copy Download .nbib Format: NLM
Share it on

Zentralbl Gynakol. 2005 Dec;127(6):385-8. doi: 10.1055/s-2005-836858.

Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company.

Zentralblatt fur Gynakologie

G R Blackledge

Affiliations

  1. AstraZeneca Pharmaceuticals, Macclesfield, UK. [email protected]

PMID: 16341982 DOI: 10.1055/s-2005-836858

Abstract

For a company or institute that wishes to develop new anti-cancer agents, it is necessary to establish a portfolio of agents to reduce the risk of failure. Success rates for developing new agents are low and therefore different biological effect areas should be explored to ensure that at least one agent targeting cancer or a specific histological sub-type of cancer is effectively developed. This paper describes how one pharmaceutical company has developed a range of different agents with the ultimate aim of developing as many of these as is technically feasible into useful new medicines for the treatment of cancer.

Substances

MeSH terms

Publication Types